The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary ...

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving ...

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) ...

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition ...

For children with severe Crohn disease, upadacitinib offers an effective induction therapy, but its benefits must be ...

Epcoritamab demonstrated a median CR of 36 months and a median progression-free survival of 37 months in LBCL patients.

Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia ...

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings ...